Why the study?
Left ventricular dilatation and low ejection fraction after acute myocardial infarction are independent indicators of poor prognosis, and the effects of early lisinopril treatment on left ventricular structure and function needed further evaluation.
Does early lisinopril treatment attenuate left ventricular dilatation and do pre-discharge echocardiographic measurements predict outcomes in patients after acute myocardial infarction?
Does early lisinopril treatment attenuate left ventricular dilatation and do pre-discharge echocardiographic measurements predict outcomes in patients after acute myocardial infarction?
Pre-discharge 2-D echocardiography predicts 6-month mortality and heart failure after MI, and early 6-week lisinopril treatment attenuates left ventricular dilatation in patients with larger infarcts.
Answers are grounded in this paper and cite their sources.
Supports pre-discharge echocardiography for post-MI risk stratification; confirms early lisinopril attenuates LV dilatation in larger infarcts.
BACKGROUND: Left ventricular dilatation and a low ejection fraction after acute myocardial infarction are independent indicators of a poor prognosis. ACE inhibitors have been shown to decrease left ventricular dilatation after myocardial infarction. In the GISSI-3 trial, patients were randomly assigned, within 24 h of onset of myocardial infarction symptoms, to 6 weeks of treatment with lisinopril, nitroglycerin, both or neither, in an open, 2 x 2 factorial design. The study showed that early treatment in relatively unselected patients with lisinopril decreases mortality at 6 weeks and severe left ventricular dysfunction. We assessed (1) the prognostic value of pre-discharge 2-D echocardiographic variables, and (2) the effects of lisinopril on the progression of left ventricular dilatation. METHODS AND RESULTS: 2-D echocardiograms were available pre-discharge in 8619 GISSI-3 trial patients discharged alive. In 6405 of these patients, a 2-D echocardiographic study was also available at 6 weeks, and at 6 months. Pre-discharge end-diastolic and end-systolic volumes, and ejection fraction predicted 6-month mortality and non-fatal clinical congestive heart failure (P < 0.01). The increase in left ventricular volumes over time was significantly reduced by 6 weeks' lisinopril treatment in patients with wall motion asynergy pre-discharge of > or = 27%. Patients with wall motion asynergy < 27% showed no dilatation and lisinopril did not affect volumes at 6 months. Patients randomized to lisinopril also had smaller volumes after withdrawal of treatment at 6 weeks. Lisinopril did not affect left ventricular ejection fraction. CONCLUSIONS: 2-D echocardiography independently contributes to pre-discharge risk stratification in terms of 6-month mortality and clinical heart failure after myocardial infarction, and early, short-term treatment with lisinopril in unselected myocardial infarction patients attenuates left ventricular dilatation; an effect evident in patients with larger infarcts. These results probably only partly explain the effect of lisinopril on total mortality concentrated in the first week after infarction.
No takes yet. Share an insight, caveat, or question.
Nicolosi et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: